Merck & Co., Inc.
Explore Merck & Co., Inc.
Core profile pages, annual revenue records, and related research hubs for this company.
CorpDigest
Merck & Co., Inc.
Explore Merck & Co., Inc.
Core profile pages, annual revenue records, and related research hubs for this company.
Annual Revenue
FY2024 Revenue
$63.6B
▲ 5.8% vs FY2023 ($60.1B)
Net Income: $17.1B
Source: 10-K
Merck & Co., Inc. reported $63.6B in revenue for fiscal year 2024. This represents a growth of 5.8% compared to the 2023 figure of $60.1B. In 2025, revenue increased to $65.0B.
Net sales grew about 5.8 percent to approximately 63.6 billion USD, led by Keytruda at around 29.5 billion USD and the March 2024 launch of Winrevair for pulmonary arterial hypertension.
| Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $65.0B | — | +2.2% |
| FY2024 | $63.6B | $17.1B | +5.8% |
| FY2023 | $60.1B | $365M | +1.4% |
| FY2022 | $59.3B | $14.5B | +21.7% |
| FY2021 | $48.7B | $13.0B | +1.5% |
| FY2020 | $48.0B | $7.1B | +2.5% |
| FY2019 | $46.8B | $9.8B | +10.7% |
| FY2018 | $42.3B | $6.2B | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.